“Its patent will expire next year, and it will be available as a generic and I will introduce it to the entire public health ...

Ken Paxton accuses the three big insulin manufacturers of conspiring with the three largest pharmacy companies to overcharge patients hundreds of dollars per dose while raking in sizable profits.

AUSTIN — Attorney General Ken Paxton sued major pharmaceutical makers and other companies Thursday, alleging they violated ...

(Reuters) - The Texas attorney general has sued leading insulin manufacturers and pharmacy benefit managers (PBMs), accusing ...

The shortage of Eli Lilly’s (LLY) blockbuster diabetes and weight loss drugs is officially over, according to the U.S. Food ...

Novo Nordisk and Eli Lilly, whose obesity drugs are some of the most in-demand drugs in the US, have drafted plans to avoid ...

Novo Nordisk’s chief scientific officer Marcus Schindler led the keynote address at ELRIG Drug Discovery 2024 in London, UK.

Novo Nordisk A/S Sponsored ADR Class B (NVO) is currently at $115.65, down $0.83 or 0.71% --Would be lowest close since Feb. 2, 2024, when it closed at $113.70 --Currently down six consecutive days; ...

Wegovy and Zepbound are still hard to get. Knockoff versions from Noom, Ro, and others are filing in the gaps.

Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, ...

Eli Lilly & Co.’s blockbuster weight-loss and diabetes drugs are no longer considered to be in shortage in the U.S., ...

England's National Health Services will offer Eli Lilly's weight-loss drug to nearly a quarter million people as part of a ...